Welcome to our dedicated page for Exicure SEC filings (Ticker: XCUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Exicure, Inc. (Nasdaq: XCUR) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, giving investors a structured view of how this clinical-stage biotechnology company reports on its hematology-focused business. Exicure’s filings describe its evolution from an early-stage nucleic acid therapy developer to a company centered on burixafor (GPC-100), a small molecule CXCR4 antagonist being developed for stem cell mobilization and as a potential chemosensitizing agent in acute myeloid leukemia (AML).
Through periodic reports and current reports on Form 8-K, Exicure provides details on clinical and operational milestones, such as financial results for each quarter, going concern assessments, and significant corporate events. For example, 8-K filings reference press releases announcing quarterly cash positions, research and development and general and administrative expenses, and management’s view that substantial additional financing is needed to fund operations and strategic alternatives.
Proxy materials on Schedule 14A (DEF 14A) outline the company’s governance structure, annual meeting agenda, director elections, advisory votes on executive compensation, and ratification of the independent registered public accounting firm. These documents also describe virtual-only annual meeting logistics and voting procedures for Exicure stockholders.
Registration statements such as the Form S-1 filed by Exicure provide further context on its status as a smaller reporting company, the listing of its common stock on The Nasdaq Capital Market under the symbol XCUR, and the potential resale of shares by selling stockholders. Additional 8-K filings address topics like changes to the board of directors, internal financing arrangements, and Nasdaq listing compliance matters.
On Stock Titan, investors can access these SEC documents alongside AI-powered summaries that highlight key points in lengthy filings, such as risk disclosures, capital needs, and updates on the burixafor development program. Real-time integration with EDGAR helps surface new 10-Q, 10-K, 8-K, proxy, and registration filings as they become available, while insider transaction reports on Form 4 and other ownership-related filings can be reviewed to understand equity activity by directors and officers.
Exicure, Inc. has obtained preliminary court approval for a global settlement of stockholder derivative matters tied to previously disclosed litigation over past handling of research data and disclosures. The settlement covers actions in federal courts in Illinois and Delaware plus a stockholder demand to the board.
Under the proposed terms, Exicure will adopt and maintain a package of corporate governance reforms for at least four years, including a new board-level Research and Data Integrity Oversight Committee and a management-level Disclosure Committee. Defendants’ insurers, rather than the company, have agreed to pay $675,000 in plaintiffs’ attorneys’ fees and expenses, subject to final court approval. A settlement hearing is scheduled for June 2, 2026, and current stockholders as of March 18, 2026 may object by written submission ahead of that date.
Exicure, Inc. reported a change on its Board of Directors. On March 25, 2026, director Sangjin Yeo submitted his resignation from the Board and the Audit Committee, effective March 27, 2026. The company stated that his resignation did not result from any disagreement regarding its operations, policies, or practices. The report was signed on behalf of Exicure by Chief Executive Officer Jung Soo Kim.
Exicure, Inc. reports that it has halted its historical biotech R&D, sold essentially all prior intellectual property, and is now focused on exploring strategic alternatives, including acquisitions and partnerships, potentially outside biotechnology and with an emphasis on Asia.
At December 31, 2025, cash and cash equivalents were about $3.7 million, with a 2025 net loss of $4.9 million and an accumulated deficit of $223.0 million, leading to “substantial doubt” about its ability to continue as a going concern without near‑term financing.
The company acquired GPCR Therapeutics USA Inc. in January 2025; GPCR USA completed a Phase 2 trial in January 2026, and Exicure plans a $1.0 million milestone payment in stock in 2026. HiTron owns about 25% of common stock, increasing governance influence concerns. Risks include Nasdaq delisting, significant legal proceedings and settlements, difficulties redeeming $2.090 million of convertible notes, unpaid rent disputes of about $0.7 million, and limited internal controls and cybersecurity resources.
Exicure, Inc. reported a smaller net loss for 2025 but highlighted serious liquidity challenges. Net loss narrowed to $4.9 million from $9.7 million in 2024, helped by a $6.0 million gain from early termination of its Chicago office lease.
Cash and cash equivalents fell sharply to $3.7 million as of December 31, 2025, from $12.5 million a year earlier. Management states this cash is not sufficient to fund operations, and that substantial additional financing is needed in the short term to pay expenses and continue exploring strategic alternatives.
Following the acquisition of GPCR Therapeutics USA Inc., research and development expenses rose to $3.3 million from zero, while general and administrative expense increased to $6.8 million from $5.4 million, mainly due to acquisition and integration costs. Revenue was $0 in 2025 versus $0.5 million in 2024.
Exicure, Inc. Chief Accounting Officer Josh Miller reported a small tax-related share disposition. On February 16, 2026, 8 shares of common stock at $4.08 per share were withheld by Exicure to cover his tax obligation upon vesting of restricted stock units. After this withholding, Miller directly holds 301 shares of Exicure common stock. This was a tax-withholding disposition under code F, not an open-market sale.
Exicure, Inc. reported a leadership change, appointing Jung Soo Kim as Chief Executive Officer and President and Gyuyeob Lee as Interim Chief Financial Officer and Secretary, effective February 11, 2026. These appointments follow the resignations of former CEO and President Andy Yoo and former CFO and Secretary Seung Ik Baik, effective February 9, 2026.
The company highlights Mr. Kim’s more than 20 years of experience in corporate strategy, capital markets and restructuring, and Mr. Lee’s background in governance restructuring, financial planning and regulatory compliance, including their current roles at AGEDB Technology. Exicure’s board also approved that CEO and Interim CFO services will be provided under executive services agreements with Innocircle Advisors Inc.
Exicure, Inc. reported significant leadership and board changes. On February 6, 2026, three directors — Andy Yoo, Seung Ik Baik, and Aejin Hwang — resigned from the Board effective February 9, 2026, with the company stating there were no disagreements over operations or policies.
The Board simultaneously appointed Jung Kyu Ham, Jung Soo Kim, and Gyeung Seog Cheon as new directors, with staggered terms through the 2026, 2027, and 2028 annual meetings, and named Mr. Cheon to the audit committee. Each new director will receive a $20,000 annual retainer.
The Board also approved a one-time $20,000 cash payment to each of the two remaining directors, Dongho Lee and Sangjin Yeo, and to outgoing director Hwang. On the same date, Yoo resigned as Chief Executive Officer and President, and Baik resigned as Chief Financial Officer and Secretary, effective February 9, 2026. The Board has not yet appointed successors, and Baik received a $150,000 separation payment.
Exicure, Inc. reported achieving the first contractual milestone under its License and Collaboration Agreement with GPCR Therapeutics Inc., tied to completing a Phase 2 clinical trial of its novel stem cell mobilizer (CXCR4 inhibitor Burixafor, GPC‑100). The milestone was reached when the Clinical Study Report was formally submitted to the U.S. Food and Drug Administration on January 16, 2026. Under the agreement, Exicure must pay $1,000,000 to GPCR Therapeutics within 30 days, and completion of this milestone also triggers a future sublicensing income‑sharing ratio that increases Exicure’s participation in the long‑term economics of the program.
Exicure HiTron Inc., a major shareholder of Exicure, Inc., has updated its ownership report after selling part of its stake. On January 21, 2026, Exicure HiTron completed a share transfer of 258,367 common shares at $4.50 per share, for total proceeds of $1,162,651.5. The shares were sold under share transfer agreements dated December 30, 2025 and were transferred to Jeon Sungchan for liquidity purposes.
After this transaction, Exicure HiTron reports beneficial ownership of 1,598,947 Exicure common shares, which represents about 25.1% of the company’s outstanding common stock. The ownership percentages are based on 6,373,869 shares outstanding as of November 3, 2025, as disclosed in Exicure’s Form 10-Q.
Exicure HiTron Inc., a more than 10% owner of Exicure, Inc. (XCUR), reported a sale of common stock. On 01/21/2026, the reporting person sold 258,367 shares of Exicure common stock at a price of $4.5 per share in an open-market transaction coded as "S" for sale.
After this transaction, Exicure HiTron Inc. beneficially owned 1,598,947 shares of Exicure common stock, held in direct ownership form. This filing is a routine Form 4 disclosure of insider activity and does not by itself describe any change to Exicure’s underlying business operations.